Case report on neonatal renal failure due to prenatal exposure of Telmisartan
Keywords:Acute renal failure, Telmisartan, oligohydramnios
Telmisartan is an antihypertensive medication, which acts as an angiotensin II receptor blocker, and has an inhibitory effect on the renin-angiotensin system. Angiotensin receptor blockers(ARBs) are contraindicated in pregnancy (category D); adverse effects have been reported in both animal and human pregnancies, but still pregnant mothers do come with this medication with consequent neonatal adverse complications. We report 2 such cases of adverse neonatal outcomes in hypertensive mothers exposed to Telmisartan during pregnancy.
Alwan S, Polifka JE, Friedman JM. Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Research. Part A Clinical and Molecular Teratology. 2005;73:123-30.
Quan A. Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Human Dev. 2006;82:23-8.
Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, Uzan S. Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol. 2004;70(8):547-9.
Celentano C, Prefumo F, di Vera E, Iannicco A, Gallo DP, Liberati M. Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker. Pediatr Nephrol. 2008;23(2):333-4.
Oppermann M, Padberg S, Kayser A, Weber-Schoendorfer C, Schaefer C. Angiotensin-II receptor 1 antagonist fetopathy--risk assessment, critical time period and vena cava thrombosis as a possible new feature. Brit J Clinical Pharmacol. 2013;75(3):822-30.